-
Igama eliphelele:UKhuseleko loMzimba-157, apentadecapeptide (15-amino acid peptide)Iqale yodwa kwijusi yesisu somntu.
-
Ulandelelwano lwe-amino acid:I-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, ubunzima bemolekyuli ≈ 1419.55 Da.
-
Xa kuthelekiswa nezinye iipeptide ezininzi, i-BPC-157 izinzile emanzini kunye nejusi yesisu, eyenza ukuba ulawulo lomlomo okanye lwesisu lube nokwenzeka ngakumbi.
IiNdlela zokuSebenza
-
I-Angiogenesis / ukuBuyiselwa kweCyculatory
-
IyaphakamisaVEGFR-2ukubonakaliswa, ukukhuthaza ukubunjwa kwemithambo yegazi emitsha.
-
Yenza iIndlela ye-Src-Caveolin-1-eNOS, ekhokelela ekukhululweni kwe-nitric oxide (NO), i-vasodilation, kunye nokuphucula umsebenzi we-vascular.
-
-
I-Anti-inflammatory & Antioxidant
-
Ukunciphisa i-cytokines e-pro-inflammatory efanaI-IL-6kwayeTNF-α.
-
Ukunciphisa ukuveliswa kwe-oxygen esebenzayo (ROS), ukukhusela iiseli kuxinzelelo lwe-oxidative.
-
-
Ukulungiswa kwezicubu
-
Ukukhuthaza ukubuyiswa kwesakhiwo kunye nokusebenza kwi-tendon, ligament, kunye neemodeli zokulimala kwemisipha.
-
Ibonelela nge-neuroprotection kwiimodeli zokulimala kwenkqubo ye-nervous central (uxinzelelo lwe-spinal cord, i-cerebral ischemia-reperfusion), ukunciphisa ukufa kwe-neuronal kunye nokuphucula i-motor / sensory recovery.
-
-
Ukulawulwa kweToni yeVascular
-
Izifundo ze-Ex vivo ze-vascular zibonisa i-BPC-157 ibangela i-vasorelaxation, ixhomekeke kwi-endothelium engaguqukiyo kunye ne-NO pathways.
-
Isilwanyana kunye ne-Vitro Comparative Data
| Uhlobo loMfuniselo | Umzekelo / ungenelelo | Umthamo / Ulawulo | Ulawulo | Iziphumo eziphambili | Idatha yokuthelekisa |
|---|---|---|---|---|---|
| I-Vasodilation (i-rat aorta, i-ex vivo) | Phenylephrine-precontracted aortic amakhonkco | BPC-157 ukuya kuthi ga100 μg/ml | Akukho BPC-157 | I-Vasorelaxation ~37.6 ± 5.7% | Yehliswe ukuya10.0 ± 5.1% / 12.3 ± 2.3%ngeNOS inhibitor (L-NAME) okanye NO scavenger (Hb) |
| Uvavanyo lweseli ye-Endothelial (HUVEC) | HUVEC inkcubeko | 1 μg/ml | Ulawulo olungaphathwanga | ↑ AKUKHO mveliso (1.35-fold); ↑ ukufuduka kweeseli | Ukufuduka kupheliswe nge-Hb |
| Imodeli yelungu le-Ischemic (impuku) | Ischemia ye-Hindlimb | 10 μg/kg/ngosuku (ip) | Akukho nyango | Ukuchacha ngokukhawuleza kokuhamba kwegazi, ↑ angiogenesis | Unyango > Ulawulo |
| Uxinzelelo lwentambo yomqolo (impuku) | I-Sacrococcygeal yoxinzelelo lwentambo yomgogodla | Isitofu se-ip enye 10 min emva kokulimala | Iqela elingaphathwanga | Ukubuyiselwa okubalulekileyo kwe-neurological and structure | Iqela lolawulo lahlala likhubazekile |
| Imodeli yeHepatotoxicity (CCl₄ / utywala) | Ukulimala kwesibindi okwenziwe ngamachiza | 1 µg okanye 10 ng/kg (ip / ngomlomo) | Ukunganyangwa | ↓ AST / ALT, ukunciphisa i-necrosis | Iqela lokulawula libonise ukulimala okukhulu kwesibindi |
| Izifundo zobutyhefu | Iimpuku, imivundla, izinja | Iidosi ezininzi / iindlela | Ulawulo lwe-placebo | Akukho tyhefu ibalulekileyo, akukho LD₅₀ ijongiwe | Inyamezeleke kakuhle nakwidosi eziphezulu |
Izifundo zoLuntu
-
Case series: I-injection ye-Intra-articular ye-BPC-157 kwizigulane ze-12 ezineentlungu zedolo → i-11 ibike ukukhululeka okukhulu kweentlungu. Unyino: akukho qela lolawulo, akukho mfama, iziphumo ezizimeleyo.
-
Ulingo lwezonyango: Uphando lweSigaba I sokhuseleko kunye ne-pharmacokinetic (NCT02637284) kumavolontiya angama-42 anempilo aqhutywe, kodwa iziphumo azikapapashwa.
Ngoku,akukho lulingo oluphezulu olulawulwa ngokungakhethiyo (RCTs)ziyafumaneka ukuqinisekisa ukusebenza kweklinikhi kunye nokhuseleko.
Ukhuseleko kunye nemingcipheko enokubakho
-
I-Angiogenesis: Iluncedo ekuphiliseni, kodwa inokukhuthaza i-tumor vascularization, ukukhula ngokukhawuleza okanye i-metastasis kwizigulana ezinomhlaza.
-
Ithamo kunye noLawulo: Isebenza kakuhle kwizilwanyana kwidosi ephantsi kakhulu (ng–µg/kg), kodwa elona thamo liphezulu lomntu kunye nendlela ihlala ingachazwa.
-
Ukusetyenziswa kwexesha elide: Akukho datha yetyhefu yexesha elide; uninzi lwezifundo zezexesha elifutshane.
-
Ubume bolawulo: Ayivunywanga njengechiza kumazwe amaninzi; ihlelwa njengeinto engavumelekangayi-WADA (i-World Anti-Doping Agency).
Uthelekiso lokuqonda kunye neMida
| Ukuthelekisa | Amandla | Ukulinganiselwa |
|---|---|---|
| Isilwanyana vs Umntu | Imiphumo emihle eqhubekayo kwizilwanyana (i-tendon, i-nerve, ukulungiswa kwesibindi, i-angiogenesis) | Ubungqina bomntu buncinci, abulawulwa, kwaye abukho ukulandelela ixesha elide |
| Uluhlu lwethamo | Isebenza kwiidosi eziphantsi kakhulu kwizilwanyana (ng–µg/kg; µg/ml in vitro) | Idosi yomntu ekhuselekileyo/esebenzayo ayaziwa |
| Ukuqalisa kwesenzo | Ukulawulwa kwangethuba emva kokulimala (umzekelo, i-10 min emva kokulimala komgogodla) kuvelisa ukubuyiswa okunamandla | Ukuba nokwenzeka kweklinikhi ngexesha elinjalo akucaci |
| Ubutyhefu | Akukho dosi ebulalayo okanye iziphumo ezibi kakhulu ezibonwa kwiintlobo ezininzi zezilwanyana | Ubuthi bexesha elide, i-carcinogenicity, kunye nokhuseleko lokuzala luhlala lungavavanywa |
Ukuqukumbela
-
I-BPC-157 ibonisa iziphumo ezinamandla zokuvuselela kunye nokukhusela kwiimodeli zezilwanyana kunye neeseli: i-angiogenesis, i-anti-inflammation, ukulungiswa kwezicubu, i-neuroprotection, kunye ne-hepatoprotection.
-
Ubungqina babantu bulinganiselwe ngokugqithisileyo, kungekho datha yovavanyo lweklinikhi eyomeleleyo ekhoyo.
-
Ngokubhekele phayaizilingo ezilawulwa ngokungenamkhethe eziyilwe kakuhleziyafuneka ukuseka ukusebenza kakuhle, ukhuseleko, idosi efanelekileyo, kunye neendlela zolawulo ebantwini.
Ixesha lokuposa: Sep-23-2025